Kidney cancer (Clifton, Va.)

Durable responses to immune checkpoint inhibitor-based regimens for metastatic clear cell renal cell carcinoma stratified by IMDC risk groups: A pooled analysis of four randomized phase 3 trials.

Pub Date : 2025-01-01 DOI: 10.1177/24684570241311419 Albert Jang, Jeffrey Y Zhong, Hamsa L S Kumar, Kevin K Zarrabi, Alec Zhu, Abby L Grier, Adam Calaway, Jonathan E Shoag, Laura Bukavina, Angela Y Jia, Prateek Mendiratta, Iris Y Sheng, Santosh Rao, Jason R Brown, Jorge A Garcia, Seunghee Margevicius, Pingfu Fu, Pedro C Barata

Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations.

Pub Date : 2024-09-05 DOI: 10.3233/KCA-240016 Arshit Narang, Georges Gebrael, Yeonjung Jo, Vinay Mathew Thomas, Haoran Li, Gliceida Galarza Fortuna, Nicolas Sayegh, Clara Tandar, Nishita Tripathi, Beverly Chigarira, Ayana Srivastava, Chadi Hage Chehade, Blake Nordblad, Benjamin L Maughan, Neeraj Agarwal, Umang Swami

Post-Metastasectomy Adjuvant Therapy in Patients with Renal Cell Carcinoma: A Systematic Review.

Pub Date : 2024-08-07 DOI: 10.3233/KCA-240006 Steven Monda, Primo N Lara, Shuchi Gulati